Symphogen

Symphogen, a subsidiary of Servier and the Antibody Center of Excellence, is primarily focused on oncology and immuno-oncology. They possess a highly efficient antibody discovery and research platform, along with comprehensive early-stage development capabilities. Their antibody platform delivers antibodies with unique functionalities, offering the potential for optimal or best-in-class combination therapies or monotherapies. Their approach and capabilities are well-suited for combination therapies, which are at the core of future cancer treatments. The rpAb developed by Symphogen represents a novel biopharmaceutical for the treatment or prevention of severe human diseases.